The MarketWatch News Department was not involved in the creation of this content.-- Cebranopadol is an investigational first-of-its kind dual NOP/MOP receptor (NMR) agonist which ...

Credit: Vertex The active ingredient in Journavx is suzetrigine, a sodium channel blocker. The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug ...

People in the study had a 32 percent reduction in pain.

Dr. Adriaan Louw has heard the term "pain revolution" before. The physical therapist and scientist has been researching chronic pain for more than 30 years. Over the decades, he has witnessed the rise ...

Medications are the most frequently recommended treatment for low back pain. Research has shown that 80% of primary care patients with low back pain were prescribed at least one medication when seen ...

Patients living with severe chronic pain don’t only have to manage a debilitating affliction. They also have to deal with the FDA making it harder for them to access potentially life-changing new ...

People with severe chronic pain were far more likely to have elevated levels of eosinophils, a type of white blood cell, a new study found, hinting at an immune link to pain – but the rise in these ...

Everyday sounds add to the torment of a person with chronic back pain, apparently because pain rewires how the brain responds ...